TrialCancer communications (London, England)2025

Efficacy and safety of first-line sintilimab plus anlotinib versus chemotherapy for metastatic non-small cell lung cancer: a phase II, open-label, randomized controlled trial.

Tianqing Chu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.